Dolutegravir/lamivudine is a new once-daily, single-pill and two-drug regimen approved for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. It has been approved in Britain as complete therapy to treat HIV as previously we were using one pill having three drugs or 03 separate pills having one drug.
The approval was based on data from the global Gemini 1 and 2 studies, which evaluated over 1,400 HIV-1 infected adults. According to the company, dolutegravir and lamivudine showed non-inferior efficacy based on plasma HIV-1 RNA <50 copies per millilitre (c/mL), at week 48 in these studies compared against three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir disoproxil fumarate/emtricitabine…
